Your browser doesn't support javascript.
loading
Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
Strati, Paolo; Ahmed, Mohamed Amin; Nastoupil, Loretta J; Feng, Lei; Hagemeister, Fredrick B; Fayad, Luis E; Rodriguez, Maria A; Samaniego, Felipe; Wang, Michael; Westin, Jason R; Lee, Hun J; Iyer, Swaminathan P; Parmar, Simrit; Ahmed, Sairah; Nair, Ranjit; Steiner, Raphael E; Noorani, Mansoor; Flowers, Christopher R; Davis, R Eric; Fowler, Nathan H; Neelapu, Sattva S.
Affiliation
  • Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ahmed MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Iyer SP; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parmar S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Steiner RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Noorani M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fowler NH; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leuk Lymphoma ; 61(6): 1380-1387, 2020 06.
Article in En | MEDLINE | ID: mdl-31971032
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Follicular Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2020 Document type: Article Affiliation country: Country of publication: